标题: ABI-H0731停药失败,39/41病毒学复发 [打印本页] 作者: sir 时间: 2020-11-6 16:12 标题: ABI-H0731停药失败,39/41病毒学复发
Vebicorvir (VBR orABI-H0731):Assembly Bio’s lead core inhibitor candidate
HBV field’s first core inhibitor combination study (Study 211) to assess off-treatment response did not achieve a meaningful rate of sustained virologic response (SVR) as 39 of 41 patients have relapsed.
Assembly Bio to host webcast and conference call today at 5:00 p.m. ET. The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of Assembly Bio’s website at https://investor.assemblybio.com/events-presentations.
For more information, see the data press release “Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection” issued today, available on Assembly Bio’s website.
Reached agreement with the Chinese regulatory body, National Medical Products Administration, Center for Drug Evaluation, and advanced discussions with the U.S. Food and Drug Administration (FDA) on a Phase 3 registrational program for VBR as a chronic suppressive therapy (CST) for HBV infection.
Entered into a license and collaboration agreement with BeiGene, Ltd. for Assembly Bio’s portfolio of three clinical-stage core inhibitors (VBR, ABI-H2158, ABI-H3733) in the China territory, including Hong Kong, Macau and Taiwan.
Entered into a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate the triple combination of VBR, RNAi therapeutic AB-729 and standard-of-care NrtI therapy in patients with chronic HBV infection.
Presented clinical data for Assembly Bio’s HBV core inhibitors in an oral presentation and three posters at EASL 2020 The Digital International Liver Congress™.
Continued to enroll patients in the ongoing multi-center, randomized, placebo-controlled Phase 2 trial to evaluate 2158 with entecavir versus placebo with entecavir in treatment naïve patients with HBeAg positive chronic HBV infection.
ABI-H3733 (3733): Assembly Bio’s third core inhibitor candidate
Continued the ongoing Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics following single ascending dose and multiple ascending dose administrations in healthy subjects.
Corporate Highlights
Appointed Gina Consylman to the Board of Directors and Audit Committee in October 2020.
Anticipated Milestones and Events
HBV Portfolio
Four abstracts, including two late-breaking submissions, will be presented at the annual meeting of the American Association for Liver Diseases (AASLD), The Liver Meeting® Digital Experience (TLMdX) being hosted virtually November 13-16, 2020.
Vebicorvir
Phase 3 registrational studies for CST expected to initiate in H1 2021 in collaboration with BeiGene.
Phase 2 triple combination study with Arbutus Biopharma expected to initiate in H1 2021.
Phase 2 triple combination study evaluating the addition of interferon to VBR and NrtI expected to initiate in H1 2021.
Interim data from Phase 2 intensification study in partially virologically suppressed patients anticipated in 2021.
2158
Interim data from Phase 2 study anticipated in 2021.